Covered recipient · General Payments record
APRIL WANG ARMSTRONG
Allopathic & Osteopathic Physicians Dermatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$448,351.87
265 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $248,614.61 | 69 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $163,868.94 | 44 |
| Travel and Lodging | $27,144.17 | 60 |
| Food and Beverage | $4,104.15 | 90 |
| Honoraria | $2,370.00 | 1 |
| Compensation for serving as faculty or as a speaker for a medical education program | $2,250.00 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
Page 2 of 6; records 51–100 of 265 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
APRIL WANG ARMSTRONG
NPI 1356477087 · CMS profile ID 152935
Allopathic & Osteopathic Physicians / Dermatology
LOS ANGELES, CA
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 6; records 51–100 of 265 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1356477087?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- APRIL WANG ARMSTRONG, NPI 1356477087, CMS profile ID 152935. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 265 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356477087?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). APRIL WANG ARMSTRONG, NPI 1356477087, CMS profile ID 152935. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 265 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356477087?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- APRIL WANG ARMSTRONG, NPI 1356477087, CMS profile ID 152935, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 265 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1356477087?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
265 matching records · $448,351.87 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 265.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Janssen Biotech, Inc. | $4,050.00 | 11/09/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078308946 | CMS |
| Janssen Biotech, Inc. | $58.02 | 11/06/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078306450 | CMS |
| LEO Pharma AS | $8,145.00 | 11/06/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152617503 | CMS |
| Galderma Laboratories, L.P. | $5.64 | 11/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145284379 | CMS |
| Lilly USA, LLC | $2,700.00 | 11/04/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155954702 | CMS |
| Boehringer Ingelheim International GmbH | $1.06 | 11/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117977202 | CMS |
| Boehringer Ingelheim International GmbH | $2.20 | 11/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117977206 | CMS |
| Boehringer Ingelheim International GmbH | $6.45 | 11/03/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117977212 | CMS |
| GENZYME CORPORATION | $2,865.00 | 10/29/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139821277 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $3,750.00 | 10/29/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1137474235 | CMS |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $2,800.00 | 10/26/2024 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1154912422 | CMS |
| LEO Pharma Inc. | $48.71 | 10/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152619169 | CMS |
| Eli Lilly and Company | $115.21 | 10/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136051235 | CMS |
| GENZYME CORPORATION | $250.00 | 10/24/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139821451 | CMS |
| GENZYME CORPORATION | $500.00 | 10/23/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139821453 | CMS |
| Lilly USA, LLC | $1,800.00 | 10/23/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155955888 | CMS |
| Galderma Laboratories, L.P. | $5.64 | 10/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1145284377 | CMS |
| ABBVIE INC. | $700.00 | 10/18/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103131485 | CMS |
| ABBVIE INC. | $700.00 | 10/18/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103131487 | CMS |
| Lilly USA, LLC | $1,800.00 | 10/18/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155952224 | CMS |
| E.R. Squibb & Sons, L.L.C. | $3,920.00 | 10/15/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101307903 | CMS |
| E.R. Squibb & Sons, L.L.C. | $2,572.50 | 10/10/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101307885 | CMS |
| Lilly USA, LLC | $1,800.00 | 10/09/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155958358 | CMS |
| E.R. Squibb & Sons, L.L.C. | $123.51 | 10/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101307897 | CMS |
| LEO Pharma Inc. | $116.71 | 10/05/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1152619167 | CMS |
| Boehringer Ingelheim International GmbH | $1.06 | 10/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117977200 | CMS |
| Boehringer Ingelheim International GmbH | $6.45 | 10/03/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117977210 | CMS |
| Novartis Pharmaceuticals Corporation | $112.47 | 09/27/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086760153 | CMS |
| ABBVIE INC. | $700.00 | 09/26/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103131483 | CMS |
| E.R. Squibb & Sons, L.L.C. | $42.56 | 09/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101307887 | CMS |
| UCB, Inc. | $86.40 | 09/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143360586 | CMS |
| UCB SA | $14.51 | 09/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113950749 | CMS |
| UCB SA | $25.67 | 09/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113950751 | CMS |
| UCB SA | $33.48 | 09/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1113950753 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.24 | 09/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101307913 | CMS |
| E.R. Squibb & Sons, L.L.C. | $17.24 | 09/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101307915 | CMS |
| Amgen Inc. | $25.04 | 09/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117192519 | CMS |
| Arcutis Biotherapeutics, Inc. | $375.00 | 09/19/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1121035740 | CMS |
| GENZYME CORPORATION | $48.14 | 09/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139821257 | CMS |
| Novartis Pharmaceuticals Corporation | $65.43 | 09/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086760155 | CMS |
| Regeneron Healthcare Solutions, Inc. | $26.49 | 09/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1114001017 | CMS |
| GENZYME CORPORATION | $4,775.00 | 09/18/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139821455 | CMS |
| Eli Lilly and Company | $8,100.00 | 09/11/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136053710 | CMS |
| Eli Lilly and Company | $3,150.00 | 09/11/2024 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136053712 | CMS |
| Boehringer Ingelheim International GmbH | $6.45 | 09/03/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117977208 | CMS |
| Eli Lilly and Company | $1.61 | 08/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136050305 | CMS |
| Eli Lilly and Company | $383.16 | 08/22/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1136049371 | CMS |
| Eli Lilly and Company | $74.77 | 08/22/2024 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155176777 | CMS |
| Eli Lilly and Company | $209.39 | 08/22/2024 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155176949 | CMS |
| Eli Lilly and Company | $5.61 | 08/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155176951 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $20,381.82 | 9 |
| PY2025 | Principal investigator | $835,540.80 | 42 |
| PY2024 | Recipient | $39,276.49 | 18 |
| PY2024 | Principal investigator | $652,921.74 | 24 |
| PY2023 | Recipient | $22,140.00 | 10 |
| PY2023 | Principal investigator | $250,134.92 | 102 |
| PY2022 | Recipient | $34,074.34 | 16 |
| PY2022 | Principal investigator | $308,373.75 | 64 |
| PY2021 | Recipient | $33,209.41 | 31 |
| PY2021 | Principal investigator | $348,028.53 | 65 |
| PY2020 | Recipient | $26,909.25 | 10 |
| PY2020 | Principal investigator | $663,687.93 | 52 |
| PY2019 | Recipient | $7,150.03 | 11 |
| PY2019 | Principal investigator | $744,610.29 | 92 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
51 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $46,486.00 | 12/29/2025 | Covered Recipient Teaching Hospital Resnick Neuropsychiatric Hospital At | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175442796 |
| Principal investigator 1 | Janssen Research & Development, LLC | $11,681.00 | 12/25/2025 | Non-covered Recipient Entity OLIVE VIEW-UCLA EDUCATION & RESEARC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175441985 |
| Recipient | Novartis Pharmaceuticals Corporation | $2,168.50 | 12/22/2025 | Covered Recipient Physician | Research Publication/ Writing Support | No dispute reported | 06/30/2026 | 1190291386 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,934.00 | 12/15/2025 | Covered Recipient Teaching Hospital Resnick Neuropsychiatric Hospital At | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442684 |
| Recipient | Regeneron Pharmaceuticals, Inc. | $340.91 | 12/01/2025 | Covered Recipient Physician | DUPIXENT CLINICAL DEVELOPMENT PROGRAM | No dispute reported | 06/30/2026 | 1184115195 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $23,672.67 | 12/01/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223268956 |
| Principal investigator 1 | Janssen Research & Development, LLC | $17,580.00 | 11/03/2025 | Covered Recipient Teaching Hospital Resnick Neuropsychiatric Hospital At | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175442679 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,906.00 | 10/27/2025 | Covered Recipient Teaching Hospital Resnick Neuropsychiatric Hospital At | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442982 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,588.00 | 10/24/2025 | Non-covered Recipient Entity OLIVE VIEW-UCLA EDUCATION & RESEARC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442009 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,137.46 | 10/21/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223268946 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $19,601.54 | 10/21/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223268948 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $31,023.58 | 10/01/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223268944 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,868.00 | 09/29/2025 | Non-covered Recipient Entity OLIVE VIEW-UCLA EDUCATION & RESEARC H INSTITUTE INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442002 |
| Principal investigator 1 | Janssen Research & Development, LLC | $37,238.00 | 09/29/2025 | Covered Recipient Teaching Hospital Resnick Neuropsychiatric Hospital At | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175442631 |
| Recipient | Amgen Inc. | $3,654.03 | 09/23/2025 | Covered Recipient Physician | A Phase 4, Multi-center, Randomized, Double-blind, Placebo-controlled Study of the Impact of Apremilast (CC-10004) on Quality of Life, Efficacy, and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life | No dispute reported | 06/30/2026 | 1246636956 |
| Principal investigator 1 | Amgen Inc. | $2,030.55 | 09/22/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon) | No dispute reported | 06/30/2026 | 1246638648 |
| Recipient | GENZYME CORPORATION | $500.00 | 09/19/2025 | Covered Recipient Physician | A Phase IIb, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter Dose Ranging Study of a Subcutaneous Anti-OX40L Monoclonal Antibody (KY1005) in Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1226125715 |
| Recipient | Novartis Pharma AG | $509.29 | 09/10/2025 | Covered Recipient Physician | CAIN-AB | No dispute reported | 06/30/2026 | 1248109097 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $16,074.45 | 09/09/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223268940 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,267.00 | 09/08/2025 | Non-covered Recipient Entity OLIVE VIEW-UCLA EDUCATION & RESEARC H INSTITUTE INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175441991 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,503.17 | 09/02/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223268938 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,817.00 | 09/01/2025 | Covered Recipient Teaching Hospital Resnick Neuropsychiatric Hospital At | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442730 |
| Principal investigator 1 | Janssen Research & Development, LLC | $52,767.00 | 09/01/2025 | Covered Recipient Teaching Hospital Resnick Neuropsychiatric Hospital At | A Phase 2b, Multicenter, Randomized, Double-blind, Placebo- and Active-controlled, Dose ranging Study to Evaluate the Efficacy and Safety of JNJ-95475939 for the Treatment of Participants with Moderate to Severe Atopic Dermatitis | No dispute reported | 06/30/2026 | 1175442837 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $21,384.09 | 08/12/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223268934 |
| Recipient | Amgen Inc. | $3,866.44 | 08/08/2025 | Covered Recipient Physician | Early initiation of Apremilast. | No dispute reported | 06/30/2026 | 1246636960 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,770.66 | 08/01/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223268922 |
| Principal investigator 1 | Janssen Research & Development, LLC | $13,759.00 | 07/31/2025 | Non-covered Recipient Entity OLIVE VIEW-UCLA EDUCATION & RESEARC H INSTITUTE INC | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Ustekinumab Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175441997 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,817.00 | 07/28/2025 | Covered Recipient Teaching Hospital Resnick Neuropsychiatric Hospital At | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442719 |
| Recipient | Boehringer Ingelheim International GmbH | $1,925.00 | 07/24/2025 | Covered Recipient Physician | BI 655130 Spesolimab - Project Committee(s) | No dispute reported | 06/30/2026 | 1220622424 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $15,563.52 | 07/17/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223268918 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,817.00 | 06/30/2025 | Covered Recipient Teaching Hospital Resnick Neuropsychiatric Hospital At | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442926 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $14,101.92 | 06/20/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223281722 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $8,892.38 | 06/12/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223281182 |
| Principal investigator 1 | Janssen Research & Development, LLC | $5,772.00 | 05/26/2025 | Covered Recipient Teaching Hospital Resnick Neuropsychiatric Hospital At | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442580 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,157.68 | 05/13/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223279408 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $15,369.48 | 05/01/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223278798 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,794.00 | 04/28/2025 | Covered Recipient Teaching Hospital Resnick Neuropsychiatric Hospital At | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442891 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $18,315.36 | 04/10/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223277814 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $47,154.00 | 04/10/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223277818 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,362.88 | 04/10/2025 | Non-covered Recipient Entity THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | TAK-279-PsO-3003 A Phase 3, multi-center, open-label Study To Evaluate The Efficacy, Safety, And Tolerability of TAK-279 in Subjects With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1223277826 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,321.00 | 03/24/2025 | Covered Recipient Teaching Hospital Resnick Neuropsychiatric Hospital At | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175443064 |
| Recipient | PFIZER INC. | $3,200.00 | 03/18/2025 | Covered Recipient Physician | ABROCITINIB CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228770245 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $11,542.86 | 03/18/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223268912 |
| Principal investigator 1 | Janssen Research & Development, LLC | $8,516.00 | 03/03/2025 | Covered Recipient Teaching Hospital Resnick Neuropsychiatric Hospital At | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442972 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $20,700.54 | 02/18/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223268910 |
| Principal investigator 1 | Incyte Corporation | $2,335.71 | 01/28/2025 | Non-covered Recipient Entity UCLA | TRuE AD1 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis | No dispute reported | 06/30/2026 | 1240605088 |
| Principal investigator 1 | Janssen Research & Development, LLC | $7,564.00 | 01/27/2025 | Covered Recipient Teaching Hospital Resnick Neuropsychiatric Hospital At | A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis | No dispute reported | 06/30/2026 | 1175442909 |
| Recipient | Amgen Inc. | $4,217.65 | 01/21/2025 | Covered Recipient Physician | A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Early, Oligoarticular Psoriatic Arthritis Despite Initial Stable Treatment With Either NSAIDS and/or = 1 Conventional Synthetic DMARD | No dispute reported | 06/30/2026 | 1246636958 |
| Principal investigator 1 | Amgen Inc. | $219,469.48 | 01/21/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASCEND) | No dispute reported | 06/30/2026 | 1246638640 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $18,656.82 | 01/16/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A STUDY ABOUT HOW WELL TAK-279 WORKS AND ITS SAFETY IN PARTICIPANTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS DURING 52 WEEKS OF TREATMENT | No dispute reported | 06/30/2026 | 1223268904 |
| Principal investigator 1 | Amgen Inc. | $41,228.00 | 01/02/2025 | Covered Recipient Teaching Hospital RONALD REAGAN UCLA | A Phase 3, Open-label, 52-week Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab (AMG 451) in Adolescent Subjects Aged ? 12 to < 18 Years With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit) | No dispute reported | 06/30/2026 | 1246638644 |